Search

Type

Audience

Category

Issue

Last updated

Recall class

Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.

Displaying 1 - 15 of 240 items.

Health alert or recall Distribution of a New Presentation of SPIKEVAX (elasomeran) COVID-19 Vaccine (0.10 mg/mL in 2.5 mL multidose vial) with English-only Vial and Carton Labels
A new presentation of SPIKEVAX (elasomeran) with a concentration of 0.10 mg/mL in a 2.5 mL multidose vial was authorized on June 01, 2022. In order to provide rapid access to the new presentation of SPIKEVAX (0.10 mg/mL, 2.5 mL multidose vial), Moderna…
AlertHealth professional risk communication | 2022-06-06
Health alert or recall Surestrips Covid-19 Antigen Test
Surestrips Covid-19 Antigen Tests are not authorized for sale in Canada as they were re-packaged into single tests and re-labelled without authorization by the manufacturers listed on the label (i.e. Artron Laboratories Inc.).  Recall start date…
RecallHealth product recall | 2022-05-30
Health alert or recall Surestrips Rapid Response Covid-19 Antigen Rapid Test Device
Surestrips Rapid Response Covid-19 Antigen Rapid Test Device are not authorized for sale in Canada as they were re-packaged into single tests and re-labelled without authorization by the manufacturers listed on the label (i.e.…
RecallHealth product recall | 2022-05-30
Health alert or recall The Newfoundland Distillery Company - Fighting Spirit: Acetaldehyde outside acceptable limit
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-04-21
Health alert or recall Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant
Sotrovimab, 500 mg IV, is unlikely to maintain efficacy against the Omicron BA.2 subvariant. Sotrovimab demonstrates reduced in vitro neutralization against the Omicron BA.2 subvariant.   Audience  Healthcare professionals responsible…
AlertHealth professional risk communication | 2022-04-14
Health alert or recall Distribution of EVUSHELD (tixagevimab and cilgavimab for injection) with English-Only Vial and Carton Labels
EVUSHELD (tixagevimab and cilgavimab for injection) was authorized by Health Canada on April 14, 2022. In order to provide rapid access to EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with…
AlertHealth professional risk communication | 2022-04-14
Health alert or recall Distribution of NUVAXOVID with English-only Vial and Carton Labels
NUVAXOVID was authorized by Health Canada on February 17, 2022. In order to provide earlier access to NUVAXOVID in the context of the global pandemic, Novavax, Inc. will distribute product vials, cartons and package inserts that are in English only for a…
AlertHealth professional risk communication | 2022-02-23
Health alert or recall Rapid Protectant Hand Sanitizer Gel: labelling
Affected lot(s) may be missing risk statements and the non medicinal ingredient carbomer on the outer label. 
RecallHealth product recall | 2022-02-23
Health alert or recall The Newfoundland Distillery Company - Fighting Spirit: Acetaldehyde outside acceptable limit
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-02-08
Health alert or recall Alcohol Antiseptic 80% (v/v) Topical Solution Hand Sanitizer: Acetaldehyde outside acceptable limit
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-02-08
Health alert or recall PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
PAXLOVID (nirmatrelvir and ritonavir) was authorized by Health Canada on January 17, 2022. PAXLOVID is not recommended in patients with severe renal impairment and requires a dosage reduction in patients with moderate renal impairment. PAXLOVID may also…
AlertHealth professional risk communication | 2022-01-17
Health alert or recall Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
There is a high risk of treatment failure with the casirivimab and imdevimab combination based on analysis of neutralization activity against selected mutations of the SARS-CoV-2 Omicron variant. The Canadian Product Monograph for casirivimab and…
AlertHealth professional risk communication | 2022-01-07
Health alert or recall SARS-COV-2 RAPID ANTIGEN TEST NASAL WITH CONTROL
The manufacturer confirmed that some SARS-COV-2  Rapid Antigen Test Nasal kits lots were erroneously distributed with Medico swabs, which are not included in the current Health Canada interim order authorization for that kit.…
RecallHealth product recall | 2021-11-26
Health alert or recall KN95 FACE MASK
The importer was informed that the specifications do not meet the requirements or the laboratories were not reliable/verifiable. Not all respirators meet the minimum 95% filtration rate required. Recall start date: 2021-05-28…
RecallHealth product recall | 2021-11-26
Health alert or recall HYNAUT KN95 PROTECTIVE FACE MASK
These respirators do not meet the prescribed standard of KN95. There is insufficient evidence to support their safety and effectiveness. This recall affects Hynaut KN95 protective face mask models C004, C012, A048, A058, and A059…
RecallHealth product recall | 2021-11-19
Report a problem or mistake on this page
What was wrong?

You will not receive a reply. Telephone numbers and e-mail addresses will be removed.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.